Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors

Fang Yang,Xie-Er Jian,Peng-Cheng Diao,Xian-Sen Huo,Wen-Wei You,Pei-Liang Zhao
DOI: https://doi.org/10.1016/j.ejmech.2020.112625
IF: 7.088
2020-10-01
European Journal of Medicinal Chemistry
Abstract:<p>On the basis of our previous work, twenty-nine novel [1,2,4]triazolo[4,3-a]pyridines possessing 3,4,5-trimethoxylphenyl groups were designed, synthesized, and evaluated as tubulin polymerization inhibitors. The bioassay results revealed that some of the compounds displayed excellent antiproliferative efficacies in the nanomolar range against HeLa cells, and the most promising derivative <strong>7i</strong> demonstrated almost comparable activity to that of the reference CA-4 and sixty-two fold more potent than the parent compound <strong>6</strong> with an IC<sub>50</sub> value of 12 nM. Importantly, <strong>7i</strong> exhibited high selectivity over the normal human embryonic kidney HEK-293 cells (IC<sub>50</sub> &gt; 100 μM). Further mechanism studies revealed that <strong>7i</strong> significantly arrested cell cycle at G2/M phase, induced apoptosis with a dose-dependent manner, and disrupted microtubule networks. Additionally, the most active compound <strong>7i</strong> effectively inhibited tubulin polymerization with a value similar to that of CA-4 (3.4 and 4.2 μM, respectively). Furthermore, molecular docking analysis suggested that <strong>7i</strong> well occupied the colchicine binding pocket of tubulin. The present study highlights that compound <strong>7i</strong> is a novel potential tubulin polymerization inhibitor and deserves further investigation for the treatment of cancers.</p>
chemistry, medicinal
What problem does this paper attempt to address?